Ra Capital Management, L.P. Sells 170,441 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

by · The Markets Daily

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ra Capital Management, L.P. sold 170,441 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $0.40, for a total transaction of $68,176.40. Following the transaction, the insider directly owned 349,907 shares of the company’s stock, valued at approximately $139,962.80. This represents a 32.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

  • On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total transaction of $55,361.25.
  • On Monday, June 15th, Ra Capital Management, L.P. sold 128,770 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.39, for a total transaction of $50,220.30.
  • On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.38, for a total transaction of $99,751.14.
  • On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $16,991.51.
  • On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $136,826.00.
  • On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $64,736.64.
  • On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $58,618.30.
  • On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Price Performance

HOWL stock traded down $0.03 during midday trading on Tuesday, reaching $0.36. The company had a trading volume of 580,233 shares, compared to its average volume of 468,701. Werewolf Therapeutics, Inc. has a 1 year low of $0.36 and a 1 year high of $2.38. The company has a market capitalization of $17.50 million, a P/E ratio of -0.29 and a beta of 0.29. The firm has a 50-day moving average price of $0.65 and a 200-day moving average price of $0.71.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. On average, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors have recently made changes to their positions in HOWL. Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at $48,000. Regal Investment Advisors LLC raised its holdings in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after buying an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after buying an additional 24,003 shares during the last quarter. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the 1st quarter valued at $79,000. Finally, Susquehanna International Group LLP raised its holdings in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after buying an additional 13,439 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on HOWL. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.75.

View Our Latest Stock Report on HOWL

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.

Read More